CEDAR KNOLLS, N.J.,
March 27, 2018 /PRNewswire/
-- MYOS RENS Technology, Inc. ("MYOS" or the "Company")
(NASDAQ: MYOS), a bionutrition and
biotherapeutics company focused on the discovery,
development and commercialization of products that improve muscle
health and performance, announced today that it has entered into a
research agreement with Rutgers
University, The State University of New Jersey, to engage Rutgers researchers in a program focused on
discovering compounds and products for promoting the growth and
development of muscle tissue.
The discovery program will be led by Joseph W. Freeman, Ph.D., Associate Professor,
Department of Biomedical Engineering at Rutgers' School of Engineering, who oversees the
University's Musculoskeletal Tissue Regeneration Laboratory
("MoTR").
"We hope this program will result in the discovery of compounds
and products that we can potentially develop as therapeutics for
improving muscle health and performance and preventing muscle loss
in disorders such as sarcopenia and cachexia," said Joseph Mannello, CEO of MYOS.
Dr. Freeman commented, "The Rutgers MoTR team is pleased to have
the opportunity to work with MYOS on discovering products that
may have the potential to address muscle wasting disorders such as
cachexia or to slow the progressive loss of lean muscle mass as a
consequence of aging."
"The program undertaken by Dr. Freeman is the first of many
programs which MYOS would seek to collaborate with Rutgers over the next several years," commented
Mannello. "We believe that working with leading researchers at
Rutgers will enable us to take
MYOS to the next stage of its
growth and development as an emerging research-focused company with
the goal of developing next generation products to address muscle
loss."
About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), "The Muscle Company™", is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product manufactured via
a proprietary process to retain and optimize its biological
activity. Fortetropin® has been clinically shown to increase muscle
size and lean body mass in conjunction with resistance training.
MYOS believes Fortetropin® has the potential to redefine existing
standards of physical health and wellness. For more information,
please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in this
release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including Qurr® products, the success of our research and
development, the results of the clinical evaluation of Fortetropin®
and its effects, the ability to enter into new partnership
opportunities and the success of our existing partnerships, the
ability to generate the forecasted revenue stream and cash flow
from sales of our products, the ability to continue increasing our
revenue and gross profit margins, the ability to achieve a
sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to update or revise any
forward-looking statement for events or circumstances
after the date on which such statement is made except
as required by law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-inc-announces-research-agreement-with-rutgers-university-focused-on-discovery-of-compounds-and-products-for-improving-muscle-health-and-performance-300619809.html
SOURCE MYOS RENS Technology, Inc.